In October, GSK raised $1.1 billion, or £885.6 million, by selling some of its shares in Haleon, reducing its stake in the consumer healthcare business to around 7.4%.

Sensodyne's brand purpose is to create an oral care future that is sensitivity‐free; we wanted to create a mobile-first digital experience that would help the brand achieve this goal. While the legacy ...

Exc. Medicines.) That is why Sensodyne wanted to show its target audience that tooth sensitivity pain, and/or experiencing bleeding gums can be overcome with Sensodyne through the power of mobile ...

GSK initially retained a 12.9% stake in Haleon ... The company continues to own well-known household brands such as Sensodyne toothpaste, Panadol and Advil pain relief medication, and Centrum ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK spun off Haleon to form a new consumer healthcare ... of well-known consumer health products across oral health (e.g. Sensodyne), vitamins and supplements (e.g. Centrum), pain relief (e.g ...

Subsequently, in July 2022, GSK spun off Haleon as an independent publicly traded company. Haleon owns popular brands such as Sensodyne, Centrum, Otrivin, and Eno. The recent sale is part of ...

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

Haleon’s household names such as Sensodyne and Paradontax toothpastes helped drive group revenue to £2.78bn. (Photo Illustration by Christof Koepsel/Getty Images) Consumer healthcare company ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...